Fibrosarcoma of bone is a malignant spindle cell tumor characterized by a herringbone or fascicular disposition of atypical, monomorphic fibroblasts and is always negative for any specific marker, which makes this tumor a diagnosis of exclusion. It can be primary or, less frequently, secondary to radiation or other pathologic conditions. It represents from 2 % to 4 % of primary bone tumors and is reported to occur from the second to the seventh decades of life. Fibrosarcoma has a preference for the metaphyses of long bones, especially the distal femur. The more important prognostic feature is histological grade. Wide resection or amputation is the indicated treatment.


Fibrosarcoma Bone Malignant Tumor Undifferentiated Sarcoma 

Recommended Reading

  1. Antonescu CR, Erlandson RA, Huvos AG. Primary fibrosarcoma and malignant fibrous histiocytoma of bone – a comparative ultrastructural study: evidence of a spectrum of fibroblastic differentiation. Ultrastruct Pathol. 2000;24(2):83–91.CrossRefPubMedGoogle Scholar
  2. Bertoni F, Capanna R, Calderoni P, Patrizia B, Campanacci M. Primary central (medullary) fibrosarcoma of bone. Semin Diagn Pathol. 1984;1(3):185–98.PubMedGoogle Scholar
  3. Dahlin DC, Ivins JC. Fibrosarcoma of bone. A study of 114 cases. Cancer. 1969;23(1):35–41.CrossRefPubMedGoogle Scholar
  4. Eyre-Brook AL, Price CH. Fibrosarcoma of bone. Review of fifty consecutive cases from the Bristol Bone Tumour Registry. J Bone Joint Surg Br. 1969;51(1):20–37.PubMedGoogle Scholar
  5. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO classification of tumors of soft tissue and bone. Lyon: IARC; 2013. p. 302–4.Google Scholar
  6. Huvos AG, Higinbotham NL. Primary fibrosarcoma of bone. A clinicopathologic study of 130 patients. Cancer. 1975;35(3):837–47.CrossRefPubMedGoogle Scholar
  7. McLeod JJ, Dahlin DC, Ivins JC. Fibrosarcoma of bone. Am J Surg. 1957;94(3):431–7.CrossRefPubMedGoogle Scholar
  8. Niini T, López-Guerrero JA, Ninomiya S, Guled M, Hattinger CM, Michelacci F, Böhling T, Llombart-Bosch A, Picci P, Serra M, Knuutila S. Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone–an array comparative genomic hybridization study. Genes Chromosomes Cancer. 2010;49(2):132–43.PubMedGoogle Scholar
  9. Papagelopoulos PJ, Galanis EC, Trantafyllidis P, Boscainos PJ, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of fibrosarcoma of bone. Am J Orthop. 2002;31(5):253–7.PubMedGoogle Scholar
  10. Romeo S, Bovée JV, Kroon HM, Tirabosco R, Natali C, Zanatta L, Sciot R, Mertens F, Athanasou N, Alberghini M, Szuhai K, Hogendoorn PC, Dei Tos AP. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Arch. 2012;461(5):561–70.CrossRefPubMedGoogle Scholar
  11. Sarhadi VK, Lahti L, Scheinin I, Ellonen P, Kettunen E, Serra M, Scotlandi K, Picci P, Knuutila S. Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. Genes Chromosomes Cancer. 2014;53(7):579–88.CrossRefPubMedGoogle Scholar
  12. Taconis WK, van Rijssel TG. Fibrosarcoma of long bones: a study of the significance of areas of malignant fibrous histiocytoma. J Bone Joint Surg Br. 1985;67:111–6.PubMedGoogle Scholar
  13. Unni KK, Inwards C. Dahlin’s bone tumors. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2010. p. 179–83.Google Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.Laboratory of Orthopaedic PathologyBuenos AiresArgentina
  2. 2.Department of PathologyA.C. Camargo Cancer CenterSão PauloBrazil

Personalised recommendations